Q32 Bio Inc. Income Statement
QTTB|8 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 8 fiscal years. All figures from audited SEC 10-K filings.
Q32 Bio Inc. reported $0 in revenue and $48M in net loss for FY2025. Revenue has declined at a 2.7% compound annual rate over the past 5 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | -$6.7M | $3.2M | $34.0M | $2.7M | $1.7M | $5.3M | $3.7M |
| SG&A Expense | $18.0M | $9.9M | $38.1M | $36.8M | $32.6M | $22.2M | $17.3M | $8.3M |
| R&D Expense | $48.1M | $31.7M | $98.4M | $93.1M | $100.4M | $89.4M | $47.9M | $21.4M |
| Operating Income | -$66.1M | -$48.3M | -$133.3M | -$95.9M | -$130.3M | -$109.9M | -$59.9M | -$29.7M |
| Interest Expense | $2.8M | $1.5M | - | - | - | - | - | - |
| Income Tax | $21.0K | $318.0K | $715.0K | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$47.7M | -$53.7M | -$5.0M | -$95.8M | -$128.7M | -$103.9M | -$55.6M | -$30.0M |
| EPS (Basic) | -$5.12 | -$153.96 | -$0.09 | -$1.73 | - | - | - | - |
| EPS (Diluted) | -$6.58 | -$153.96 | -$0.09 | -$1.73 | -$2.80 | -$2.47 | -$1.95 | -$12.10 |
| Shares Outstanding | 12.2M | 359.6K | 57.5M | 57.2M | 50.3M | 45.1M | 37.4M | 2.6M |
| Operating Margin | - | 725.5% | -4154.6% | -282.4% | -4821.0% | -6599.2% | -1126.0% | -805.0% |
| Profit Margin | - | 808.0% | -156.0% | -281.9% | -4762.9% | -6237.4% | -1044.3% | -814.1% |